Valuation: Agios Pharmaceuticals, Inc.

Market Cap 1.95B 1.67B 1.56B 1.43B 2.7B 187B 2.72B 18.49B 7.19B 93.69B 7.32B 7.16B 310B P/E 2026 *
-5.75x
P/E 2027 * -8.85x
Enterprise Value 1.69B 1.45B 1.36B 1.24B 2.34B 162B 2.36B 16.04B 6.24B 81.31B 6.35B 6.21B 269B EV / Sales 2026 *
9.27x
EV / Sales 2027 * 5.15x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day-1.36%
1 week-2.94%
Current month+8.73%
1 month-10.23%
3 months+15.99%
6 months+7.40%
Current year+19.91%
1 week 32.61
Extreme 32.61
35.98
1 month 29.15
Extreme 29.15
38.74
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 2022-08-07
Director of Finance/CFO 51 2022-09-25
Chief Tech/Sci/R&D Officer 47 2021-08-31
Director TitleAgeSince
Director/Board Member 66 2014-12-08
Director/Board Member 73 2015-06-22
Director/Board Member 73 2017-05-26
Date Insider Type Main position Quantity % Market Cap.
8/4/26 Sell

Chief Technology Officer

-30,000 0.0504%
7/8/26 Free

Director

2,894 0.0049%
7/1/26 Fiscal year

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%-2.94%-15.88%+22.75% 1.95B
-4.31%-6.62%+65.79%+98.02% 69.06B
+1.09%+0.41%+48.07%+86.19% 63.06B
-3.22%+23.17%+1.75%-5.23% 28.34B
-1.42%-3.38%-5.99%+465.34% 27.07B
+7.41%+7.45%+56.85%+17.70% 25.45B
+2.15%+2.52%+37.00%-16.17% 19.69B
+5.36%+4.61%+270.18%+415.10% 19.19B
+0.10%-3.50%+11.43%+519.16% 15.95B
+0.87%+4.26%+41.21%+150.80% 13.52B
Average +1.22%+2.65%+51.04%+175.37% 28.33B
Weighted average by Cap. +0.49%+1.63%+54.82%+152.21%

Financials

2026 *2027 *
Net sales 182M 156M 146M 134M 252M 17.47B 255M 1.73B 673M 8.77B 685M 670M 29.03B 352M 301M 282M 258M 486M 33.66B 491M 3.33B 1.3B 16.9B 1.32B 1.29B 55.92B
Net income -338M -290M -271M -248M -468M -32.37B -473M -3.21B -1.25B -16.25B -1.27B -1.24B -53.78B -229M -197M -184M -168M -317M -21.97B -321M -2.18B -846M -11.03B -861M -843M -36.5B
Net Debt -258M -221M -207M -189M -356M -24.67B -360M -2.44B -950M -12.39B -967M -946M -40.99B -137M -118M -110M -101M -190M -13.16B -192M -1.3B -507M -6.61B -516M -505M -21.86B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
26-08-24 US$32.64 -1.36% 635,734
26-08-21 US$33.09 -1.61% 577,552
26-08-20 US$33.63 -4.24% 697,493
26-08-19 US$35.12 +2.09% 1,690,406
26-08-18 US$34.40 +2.29% 1,187,837
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.64USD
Average target price
45.75USD
Spread / Average Target
+40.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock